197 related articles for article (PubMed ID: 37006256)
1. Histone acetylation-related IncRNA: Potential biomarkers for predicting prognosis and immune response in lung adenocarcinoma, and distinguishing hot and cold tumours.
Li R; Qiu T; Zhou Q; He F; Jie C; Zheng X; Lu Z; Wu Q; Xie C
Front Immunol; 2023; 14():1139599. PubMed ID: 37006256
[TBL] [Abstract][Full Text] [Related]
2. Histone acetylation modification regulator-mediated tumor microenvironment infiltration characteristics and prognostic model of lung adenocarcinoma patients.
Wang W; Shen Y; Zhang P; Liu L; Sha X; Li H; Wang S; Zhang H; Zhou Y; Shi J
J Thorac Dis; 2022 Oct; 14(10):3886-3902. PubMed ID: 36389327
[TBL] [Abstract][Full Text] [Related]
3. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
Front Immunol; 2022; 13():916800. PubMed ID: 35860239
[TBL] [Abstract][Full Text] [Related]
4. Molecular subgroup establishment and signature creation of lncRNAs associated with acetylation in lung adenocarcinoma.
Chen H; Wang Y; Shao C; Guo K; Liu G; Wang Z; Duan H; Pan M; Ding P; Zhang Y; Han J; Yan X
Aging (Albany NY); 2024 Jan; 16(2):1276-1297. PubMed ID: 38240708
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
Front Oncol; 2023; 13():972558. PubMed ID: 37064115
[TBL] [Abstract][Full Text] [Related]
6. m
Xu F; Huang X; Li Y; Chen Y; Lin L
Mol Ther Nucleic Acids; 2021 Jun; 24():780-791. PubMed ID: 33996259
[TBL] [Abstract][Full Text] [Related]
7. Construction and validation of a histone acetylation-related lncRNA prognosis signature for ovarian cancer.
Hu XQ; Zhang XC; Li ST; Hua T
Front Genet; 2022; 13():934246. PubMed ID: 36313424
[TBL] [Abstract][Full Text] [Related]
8. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma.
Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J
Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546
[TBL] [Abstract][Full Text] [Related]
9. Molecular typing and prognostic model of lung adenocarcinoma based on cuprotosis-related lncRNAs.
Zheng M; Zhou H; Xie J; Zhang H; Shen X; Zhu D
J Thorac Dis; 2022 Dec; 14(12):4828-4845. PubMed ID: 36647499
[TBL] [Abstract][Full Text] [Related]
10. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
Li F; Niu Y; Zhao W; Yan C; Qi Y
Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
[TBL] [Abstract][Full Text] [Related]
11. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma.
Zeng C; Yu H; Liu X; Liu Q; Jin J
Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457
[TBL] [Abstract][Full Text] [Related]
12. Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma.
Wang H; Lu X; Chen J
BMC Med Genomics; 2022 Dec; 15(1):254. PubMed ID: 36503492
[TBL] [Abstract][Full Text] [Related]
13. Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma.
Xu Y; Tao T; Li S; Tan S; Liu H; Zhu X
Front Genet; 2022; 13():975905. PubMed ID: 36313456
[No Abstract] [Full Text] [Related]
14. Vesicle-mediated transport-related genes are prognostic predictors and are associated with tumor immunity in lung adenocarcinoma.
Qian C; Jiang Z; Zhou T; Wu T; Zhang Y; Huang J; Ouyang J; Dong Z; Wu G; Cao J
Front Immunol; 2022; 13():1034992. PubMed ID: 36524130
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma.
Zhang H; Liu M; Yang Z; Du G; Yu B; Gui Y; Cao L; Li X; Tan B
Sci Rep; 2022 Jul; 12(1):12785. PubMed ID: 35896612
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma.
Tian L; Wang Y; Tian J; Song W; Li L; Che G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
[TBL] [Abstract][Full Text] [Related]
17. Identification of immune-associated lncRNAs as a prognostic marker for lung adenocarcinoma.
He C; Yin H; Zheng J; Tang J; Fu Y; Zhao X
Transl Cancer Res; 2021 Feb; 10(2):998-1012. PubMed ID: 35116427
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis.
Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L
BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550
[TBL] [Abstract][Full Text] [Related]
19. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification.
Gao C; Kong N; Zhang F; Tang T; Li J; Ding H; Sun Z; Wu L; Xu M
BMC Med Genomics; 2022 Jan; 15(1):15. PubMed ID: 35093068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
